Skip to main content

User account menu

  • Log in
  • Register
  • Contact
BandwidthHigh

Language switcher

  • English
  • Français
  • Español

Main navigation

    • Our work
    • Rationale
    • IDDO Team
    • Contact us
    • IDDO Board
    • IDDO Data Access Committee
    • Contributing data
    • Accessing data
    • IDDO data sharing registrations
    • COVID-19
    • Ebola
    • Malaria
    • Visceral leishmaniasis
    • Medicine Quality
    • Antimicrobial Resistance
    • Schistosomiasis & STHs
    • Chagas Disease
    • Prospective disease platforms
    • Febrile illness
    • Tools & resources
    • Publications
  • News

WWARN News

Please visit WWARN's website for regular updates on malaria and sign up for the WWARN newsletter here. 

Credit: Pearl Gan
MQPH 2018 conference
Friday, 21 September 2018

First ever international conference on Medicine Quality and Public Health starts soon in Oxford

The Infectious Diseases Data Observatory (IDDO), together with many partners including the United States Pharmacopeia (USP), the Concept Foundation, the Mahidol Oxford Tropical Medicine Research Unit (MORU) and the Wellcome Trust will host the first Medicine Quality and Public Health conference at K...
Sama Cherif presenting at ‘Data-sharing for global research good’ symposium
Tuesday, 18 September 2018

9th EDCTP Forum starts this week

We are delighted to attend the 9th EDCTP Forum in Lisbon, Portugal this week.
img-20180918-wa0003.jpg
Tuesday, 18 September 2018

9th EDCTP Forum starts this week

We are delighted to attend the 9th EDCTP Forum in Lisbon, Portugal this week.
The economic costs of antimicrobial resistance (AMR) are higher than the sales price of most popular antibiotics, according to a recent MORU/IDDO study. Curbing the unnecessary use of antibiotics is key to dealing with the AMR issue head on, particularly in SE Asia, which has the highest rates of AMR and a big, informal medicine dispensing sector that aggravates the AMR problem. ©2018 MORU/Wellcome.
Wednesday, 22 August 2018

Study details high hidden economic costs of antibiotic consumption

Bangkok / Oxford, 22 August 2018 – The economic costs of antimicrobial resistance (AMR) for every course of antibiotics are considerable, and much higher than their purchase cost, say researchers.
Credit: iStock
Friday, 3 August 2018

Applications Open for Global Health Journalism Fellowship

The 2018 Global Health Journalism Fellowship will invite outstanding young journalists to participate in the first ever international conference on Medicine Quality and Public Health at the University of Oxford. Application deadline is 12 August 2018
alex_kumar_resized.png
Monday, 23 July 2018

DFID announces support for triple ACT trials in Asia and Africa

The UK’s Department for International Development (DFID) recently announced that it will commit £9.2 million (USD 13.15 million) of funding to support a new malaria research programme lead by the Mahidol-Oxford Research Unit (MORU). The programme entitled ‘Development of Triple Artemisinin Combinati...
wwarn_toolkit_v7.png
Monday, 23 July 2018

Have you seen the updated WWARN toolkit?

Have you heard of the Malaria Clinical Trials Toolkit? The ‘toolkit’ aims to improve the quality and standard of trial data by creating a step-by-step guide for researchers and clinicians on how to design, implement and analyse malaria clinical trials.
image_2_asia.jpg
Friday, 20 July 2018

Krintafel (tafenoquine) approved for P. vivax malaria

GSK and Medicines for Malaria Venture (MMV) announce FDA approval of single-dose treatment Krintafel (tafenoquine) to prevent the relapse of P. vivax malaria.
vivax_-_pearl_gan.jpg
Thursday, 19 July 2018

New evidence supports radical treatment of P. vivax

WWARN's Clinical Group has published results supporting the need for a radical cure strategy to tackle one of the most debilitating forms of malaria caused by the Plasmodium vivax parasite.
prof_ogo_image.jpg
Tuesday, 17 July 2018

WWARN pays tribute to Prof Ogobara Doumbo

The WWARN network is very saddened by the news of the passing of Prof Ogobara Doumbo on Saturday 9 June in Marseille, France. Prof Doumbo was a long-standing WWARN partner and highly respected for his contribution to the malaria community through co-founding the Centre for Malaria Research & Trainin...
wwarn-menzies-team-first_world_congress-malaria-july-2018_photo-jutt-murfat.jpg
Monday, 2 July 2018

Spotlight on P. vivax at the First Malaria World Congress

WWARN’s Clinical Group led by Professor Ric Price joined government ministers, international institutes, malaria experts and civil society organisations in Melbourne Australia for the First Malaria World Congress 1-5 July 2018. Discussions focussed on elimination efforts, cross-sectoral collaboratio...
large2-malaria-in-pregnancy-allan_gichigi_kenyaun_development_programme_0.jpg
Tuesday, 12 June 2018

Small children and pregnant women may be underdosed with widely used antimalarial drug

Current recommended treatment regimens for the most widely used medicine for uncomplicated Plasmodium falciparum malaria may be sub-optimal for small children and pregnant women according to a study led by Prof. Joel Tarning, Head of Pharmacometrics at the WorldWide Antimalarial Resistance Network (...
Credit: United States Pharmacopeial Convention (USP)
Thursday, 31 May 2018

Experts to seek consensus on tackling poor quality medicines

A pioneering conference will bring leading professionals from all over the world to Oxford, UK to discuss strategies for tackling poor quality medical products on a global scale.
african_malaria_community_photo.jpg
Friday, 11 May 2018

Researchers develop an age-based regimen for single low-dose primaquine to block transmission of malaria in sub-Saharan Africa

The World Health Organization (WHO) recommended in 2012 to add single low-dose primaquine (SLDPQ) to standard artemisinin based combination treatments (ACTs) to block the transmission of Plasmodium falciparum malaria. The target dose of 0.25 mg base/kg body weight (15 mg in a 60 kg adult) was consid...
bill-gates-malaria-summit-april-2018.jpg
Wednesday, 25 April 2018

Commonwealth leaders urged to halve malaria cases within five years

The Commonwealth Malaria Summit last week in London (part of CHOGM 2018) welcomed Bill Gates and 12 Heads of State, 2 Deputy Heads of State and many international organisations on Wednesday 18th April. This fantastic event resulted in more than £2.9bn / $4.1bn pledged from Governments, the private s...
img_5170_0.jpg
Wednesday, 25 April 2018

WWARN team enjoys MIM 2018

We had a fantastic time at the Multilateral Initiative on Malaria’s 7th Pan-African meeting in Dakar, Senegal, 15-20 April, 2018. Thank you for joining us!
clinic_in_bamako-dominic_chavezworld_bank-2_0.jpg
Tuesday, 10 April 2018

Treatment for malaria and malnutrition could impair normal height growth: Study

Children suffering from malaria and malnutrition might experience diminished height growth when treated for both conditions simultaneously, according to a recently published article.
IDDO/ Mehul Dhorda
Monday, 5 March 2018

Study analyses AMR networks in low- and middle-income countries

A new study published today reveals the challenges of establishing sustainable and effective networks to tackle resistance to antimicrobial medicines in low- and middle-income countries (LMICs).
Boston University School of Public Health/ Population Health Exchange
Friday, 23 February 2018

Oxford University to host 2018 Quality of Medical Products and Public Health short course

The fourth Quality of Medical Products and Public Health course will take place in Oxford this year, from 17-21 September, at Wolfson College. This multidisciplinary course is aimed at professionals who are interested in the quality of medical products. The application deadline is 18 May.
An estimated 1 in 10 medical products circulating in low- and middle-income countries is either substandard or falsified
Wednesday, 29 November 2017

1 in 10 medical products in developing countries is substandard or falsified

Two new WHO publications highlight the prevalence and impact of substandard and falsified medical products. An estimated 1 in 10 medical products circulating in low- and middle-income countries is either substandard or falsified, according to new research from the World Health Organization (WHO).

Pagination

  • First page « First
  • Previous page ‹‹
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Current page 7
  • Page 8
  • Page 9
  • Next page ››
  • Last page Last »
Sign up for our newsletter Twitter LinkedinIDDO on YoutubeRSS

Footer menu

  • Cookies
  • Privacy Notice
  • Accessibility
  • Sitemap
  • Terms of use
© 2021 Infectious Diseases Data Observatory